home / stock / trsbf / trsbf news
2023-11-05 02:15:00 ET Summary Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for its next-gen PARP1 inhibitor to Germany’s Merck KGaA. BioLineRx, an Israeli biotech, out-licensed China rights to a stem cell mobilizer for multiple myeloma and stem cell disease...
BeiGene began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong and Shanghai. Jinan Qilu Pharma entered a $300 million agreement to acquire greater China rights to an RNAi therapy for hepatitis B developed by Ar...
3SBio (TRSBF): FY GAAP EPS of RMB1.41B.Revenue of RMB5.58B (+4.9% Y/Y)Press Release For further details see: 3SBio reports FY 2020 results
Deals and Financings BeiGene (NSDQ: [[BGNE]]; HK: 06160), a Beijing oncology drug biopharma, announced a $2.1 billion private placement that will bring its cash holdings to almost $5.5 billion. The company is developing a portfolio of 25 candidates, with several of them in (or soon-to-st...
3SBio ( OTC:TRSBF ): FY GAAP EPS of RMB1.17B. Revenue of RMB4.58B (22.7% Y/Y). Press Release More news on: 3SBio Inc., Earnings news and commentary,